[The MIRAGE Trial (MRI-guided stereotactic body radiotherapy for prostate cancer) - Precision at its best?].
作者信息
Ehret Felix
机构信息
Department of Radiation Oncology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Charité - Universitätsmedizin Berlin, Berlin, Germany; German Cancer Consortium (DKTK), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
出版信息
Strahlenther Onkol. 2024 Mar;200(3):255-258. doi: 10.1007/s00066-023-02194-3. Epub 2024 Jan 5.
Abstract
摘要
相似文献
1
[The MIRAGE Trial (MRI-guided stereotactic body radiotherapy for prostate cancer) - Precision at its best?].
Strahlenther Onkol. 2024 Mar;200(3):255-258. doi: 10.1007/s00066-023-02194-3. Epub 2024 Jan 5.
2
Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
BMC Cancer. 2021 May 11;21(1):538. doi: 10.1186/s12885-021-08281-x.
3
Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy in Prostate Cancer: 2-year Outcomes from the MIRAGE Randomized Clinical Trial.
Eur Urol. 2025 Jun;87(6):622-625. doi: 10.1016/j.eururo.2024.10.026. Epub 2024 Nov 13.
4
Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial.
JAMA Oncol. 2023 Mar 1;9(3):365-373. doi: 10.1001/jamaoncol.2022.6558.
5
Functional imaging guided stereotactic ablative body radiotherapy (SABR) with focal dose escalation and bladder trigone sparing for intermediate and high-risk prostate cancer: study protocol for phase II safo trial.
Radiat Oncol. 2024 May 3;19(1):54. doi: 10.1186/s13014-024-02440-7.
6
Bladder filling dynamics during online adaptive prostate stereotactic body radiotherapy: Rationale for using an empty bladder workflow for treatment.
Radiother Oncol. 2025 Aug;209:110978. doi: 10.1016/j.radonc.2025.110978. Epub 2025 Jun 2.
7
The role of adaptive planning in margin-reduced, MRI-guided stereotactic body radiotherapy to the prostate bed following radical prostatectomy: Post-hoc analysis of a phase II clinical trial.
Radiother Oncol. 2023 Jun;183:109631. doi: 10.1016/j.radonc.2023.109631. Epub 2023 Mar 18.
8
Enhancing Delivery Efficiency on the Magnetic Resonance-Linac: A Comprehensive Evaluation of Prostate Stereotactic Body Radiation Therapy Using Volumetric Modulated Arc Therapy.
Int J Radiat Oncol Biol Phys. 2025 Jul 15;122(4):976-985. doi: 10.1016/j.ijrobp.2024.10.028. Epub 2024 Oct 26.
9
Analysis of online plan adaptation for 1.5T magnetic resonance-guided stereotactic body radiotherapy (MRgSBRT) of prostate cancer.
J Cancer Res Clin Oncol. 2023 Feb;149(2):841-850. doi: 10.1007/s00432-022-03950-1. Epub 2022 Feb 24.
10
MR-guided radiotherapy for prostate cancer: an inevitable transition?
Curr Opin Urol. 2025 Sep 1;35(5):562-567. doi: 10.1097/MOU.0000000000001315. Epub 2025 Jul 4.
本文引用的文献
1
Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: A systematic review and meta-analysis.
Cancer. 2023 Oct 1;129(19):3044-3052. doi: 10.1002/cncr.34836. Epub 2023 Jul 24.
2
Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial.
JAMA Oncol. 2023 Mar 1;9(3):365-373. doi: 10.1001/jamaoncol.2022.6558.
3
The MIRAGE Trial-Optical Illusion or the Future of Prostate Stereotactic Radiotherapy?
JAMA Oncol. 2023 Mar 1;9(3):373-375. doi: 10.1001/jamaoncol.2022.6334.
4
Magnetic resonance imaging-guided radiotherapy for intermediate- and high-risk prostate cancer: Trade-off between planning target volume margin and online plan adaption.
Phys Imaging Radiat Oncol. 2022 Jul 3;23:92-96. doi: 10.1016/j.phro.2022.06.013. eCollection 2022 Jul.
5
Time-Driven Activity-Based Costing Comparison of CT-Guided Versus MR-Guided SBRT.
JCO Oncol Pract. 2020 Nov;16(11):e1378-e1385. doi: 10.1200/JOP.19.00605. Epub 2020 Jun 15.
6
The transformation of radiation oncology using real-time magnetic resonance guidance: A review.
Eur J Cancer. 2019 Nov;122:42-52. doi: 10.1016/j.ejca.2019.07.021. Epub 2019 Oct 12.
7
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Lancet Oncol. 2019 Nov;20(11):1531-1543. doi: 10.1016/S1470-2045(19)30569-8. Epub 2019 Sep 17.
8
Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies.
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):778-789. doi: 10.1016/j.ijrobp.2019.03.051. Epub 2019 Apr 6.
9
Toward planning target volume margin reduction for the prostate using intrafraction motion correction with online kV imaging and automatic detection of implanted gold seeds.
Pract Radiat Oncol. 2018 Nov-Dec;8(6):422-428. doi: 10.1016/j.prro.2018.04.008. Epub 2018 Apr 25.
10
The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review.
Support Care Cancer. 2016 Aug;24(8):3669-76. doi: 10.1007/s00520-016-3297-9. Epub 2016 Jun 3.
Zotero 插件